Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02406677 · ClinicalTrials.gov registry record · Phase 4

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

A Phase 4 study of Cost Sharing, Acute Coronary Syndrome, sponsored by AstraZeneca.

Completed
Registry status
Phase 4
Development phase
11,001
Enrollment target
20
Study locations

NCT02406677 is a Phase 4 study of Cost Sharing, Acute Coronary Syndrome that has completed, run by AstraZeneca. The registered enrollment target is 11,001 participants. The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02406677, a Phase 4 study of Cost Sharing, Acute Coronary Syndrome, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 4
Development phase
11,001 participants
Enrollment target
20
Study locations

Study Summary

Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication, patient adherence, and clinical outcomes. The ARTEMIS trial is a practical multicenter, cluster- randomized clinical trial that will assess the impact of copayment reduction by equalizing the copayment of clopidogrel and ticagrelor. ARTEMIS will assess prescribing patterns, patient medication adherence, and clinical outcomes up to one year. We hypothesize that reducing out--of--pocket cost for P2Y12 receptor inhibitor will lead to improved adherence. Additionally, copayment reduction of both generic and brand antiplatelet agents may lead to a reduction in MACE risk. This is in part due to greater adherence to an evidence--based secondary prevention medication. Additionally the reduction in MACE may reflect greater selection of a more potent antiplatelet agent that has been shown to reduce MACE in randomized clinical trials, as provider choice of antiplatelet therapy will be primarily driven by risk- benefit assessment rather than the cost burden to the patient.

Conditions Studied

Cost Sharing, Acute Coronary Syndrome

Interventions

  • OTHER Study voucher card

Study Locations (20)

California

  • Research Site - Escondido
  • Research Site - Huntington Beach
  • Research Site - Loma Linda
  • Research Site - Los Angeles
  • Research Site - Los Angeles
  • Research Site - Northridge
  • Research Site - Pasadena
  • Research Site - Riverside

Alabama

  • Research Site - Birmingham
  • Research Site - Huntsville
  • Research Site - Mobile
  • Research Site - Mobile

Arkansas

  • Research Site - Fayetteville
  • Research Site - Fort Smith
  • Research Site - Jonesboro
  • Research Site - Little Rock

Arizona

  • Research Site - Cottonwood
  • Research Site - Flagstaff
  • Research Site - Phoenix

Alaska

  • Research Site - Anchorage

Trial Details

FieldValue
Enrollment Target 11,001 participants
Start Date 2015-06-05
Est. Completion 2017-10-23
Phase Phase 4

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02406677

The ClinicalTrials.gov registry entry for NCT02406677 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 11,001 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cost Sharing, Acute Coronary Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Study voucher card is the first listed.

NCT02406677 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Arkansas.

Frequently Asked Questions

What is clinical trial NCT02406677 about?

NCT02406677 is a clinical study titled "Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study". Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication, patient adherence, and clinical outcomes. The ARTEMIS trial is a practical multicenter, cluster- randomized clinical trial that will assess t...

What is the current status of trial NCT02406677?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 11,001 participants. The study started on 2015-06-05. Estimated completion is 2017-10-23.

What conditions does trial NCT02406677 study?

This clinical trial studies the following conditions: Cost Sharing, Acute Coronary Syndrome.

What interventions are being tested in trial NCT02406677?

The interventions under investigation include: Study voucher card (OTHER).

Who is sponsoring clinical trial NCT02406677?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02406677 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Explore more on PlainTrial

Cost Sharing, Acute Coronary Syndrome

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.